Effects of Aspirin on Vitreous/Preretinal Hemorrhage in Patients With Diabetes MellitusEarly Treatment Diabetic Retinopathy Study Report No. 20
Emily Y. Chew, MD;
Michael L. Klein, MD;
Robert P. Murphy, MD;
Nancy A. Remaley, MS;
Frederick L. Ferris III, MD;
Early Treatment Diabetic Retinopathy Study Research Group
Arch Ophthalmol. 1995;113(1):52-55.
Abstract
| |
Objective
To assess whether the use of aspirin exacerbates the severity or duration of vitreous/preretinal hemorrhages in patients with diabetic retinopathy.
Design
The Early Treatment Diabetic Retinopathy Study (ETDRS), a multicenter randomized clinical trial, was designed to assess the effect of photocoagulation and aspirin on 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy.
Intervention
Patients were randomly assigned to either an aspirin (650 mg/d) or a placebo group. One eye of each patient was randomly assigned to early photocoagulation and the other to deferral of photocoagulation.
Main Outcome Measures
The severity and duration of the vitreous/preretinal hemorrhages were determined from gradings of the annual, seven standard stereoscopic field, fundus photographs. Clinical examinations scheduled every 4 months also provided information on the presence and duration of hemorrhages.
Results
Annual fundus photographs of eyes assigned to deferral of photocoagulation revealed vitreous/preretinal hemorrhages at some time during follow-up in 564 patients (30%) assigned to the placebo group and 585 patients (32%) assigned to the aspirin group (P=.48). Based on gradings of fundus photographs, there were no statistical differences in the severity of vitreous/preretinal hemorrhages (P=.11) or their rate of resolution (P=.86) between the groups. Clinical examination of eyes assigned to deferral of photocoagulation revealed 721 eyes (39%) assigned to the aspirin group and 689 (37%) assigned to the placebo group that had vitreous/preretinal hemorrhages during the course of the study (P=.30). Again, no statistically significant difference was found between the rates of resolution, as assessed clinically, between the two treatment groups (P=.43).
Conclusions
As previously reported, the use of aspirin did not increase the occurrence of vitreous/preretinal hemorrhages in patients enrolled in the ETDRS. The data presented in this report demonstrate that the severity and duration of these hemorrhages were not significantly affected by the use of aspirin and that there were no ocular contraindications to its use (650 mg/d) in persons with diabetes who require it for treatment of cardiovascular disease or for other medical indications.
Author Affiliations
From the National Eye Institute, National Institutes of Health, Bethesda, Md (Drs Chew and Ferris and Ms Remaley); the Casey Eye Institute, Oregon Health Sciences University, Portland (Dr Klein); and The Retina Institute of Maryland, Baltimore (Dr Murphy). A list of the Early Treatment Diabetic Retinopathy Study (EDTRS) investigators appears at the end of ETDRS report No. 7 (Ophthalmology. 1991;98:741-756).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review: Aspirin and Diabetes Mellitus: revisiting an old player
Manrique et al.
Ther Adv Cardiovasc Dis 2008;2:37-42.
ABSTRACT
Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT
| FULL TEXT
Use of Aspirin to Reduce Risks of Cardiovascular Disease in Patients With Diabetes: Clinical and research challenges
Hennekens et al.
Diabetes Care 2004;27:2752-2754.
FULL TEXT
How do you know?
Rosenbaum et al.
Br J Ophthalmol 2004;88:980-981.
FULL TEXT
Review: Which patients with diabetes should receive which antiplatelet agents?
Lowe
British Journal of Diabetes & Vascular Disease 2002;2:157-160.
ABSTRACT
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Collaboration
BMJ 2002;324:71-86.
ABSTRACT
| FULL TEXT
Age-Related Maculopathy in a Randomized Trial of Low-Dose Aspirin Among US Physicians
Christen et al.
Arch Ophthalmol 2001;119:1143-1149.
ABSTRACT
| FULL TEXT
Aspirin in Diabetes: Beware of Retinopathy
Ong and Kajubi
Arch Intern Med 2000;160:3004-3004.
FULL TEXT
Peculiar Macular Hemorrhage
Sarraf and Schwartz
Arch Ophthalmol 2000;118:296-297.
FULL TEXT
Treatment of Diabetic Retinopathy
Ferris et al.
NEJM 1999;341:667-678.
FULL TEXT
Ophthalmology
Levin
JAMA 1996;275:1834-1836.
ABSTRACT
ASPIRIN IS SAFE FOR DIABETICS WITH RETINOPATHY.
JWatch General 1995;1995:3-3.
FULL TEXT
|
